Replimune Group Stock Short Interest Rises to 36.13%
Investivoq ShortTracker
Replimune Group short interest was 36.13% of the float on October 30th, according to new data we received from Benzinga. Short interest totaled 24,609,876 shares, which was an increase of 6.23% from October 15th.
It is estimated that it would take 8.31 days for short sellers to buy back their shares, with current trading volumes.
Replimune Group Hedge Fund Activity
We have seen 117 institutional investors add shares of Replimune Group stock to their portfolio, and 120 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RIDGEBACK CAPITAL INVESTMENTS L.P. added 7,310,656 shares (+inf%) to their portfolio in Q2 2026, for an estimated $80,928,961
- PRICE T ROWE ASSOCIATES INC /MD/ removed 6,500,470 shares (-80.0%) from their portfolio in Q2 2026, for an estimated $71,960,202
- BOXER CAPITAL MANAGEMENT, LLC added 2,808,000 shares (+239.0%) to their portfolio in Q2 2026, for an estimated $31,084,560
- BLACKROCK, INC. added 2,719,296 shares (+43.6%) to their portfolio in Q2 2026, for an estimated $30,102,606
- LOGOS GLOBAL MANAGEMENT LP added 2,500,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $27,675,000
- AQR CAPITAL MANAGEMENT LLC added 2,310,746 shares (+904.4%) to their portfolio in Q2 2026, for an estimated $25,579,958
- GOLDMAN SACHS GROUP INC added 2,263,742 shares (+99.4%) to their portfolio in Q2 2026, for an estimated $25,059,623
To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.
Replimune Group Insider Trading Activity
Replimune Group insiders have traded $REPL stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $REPL stock by insiders over the last 6 months:
- SUSHIL PATEL (Chief Executive Officer) has made 0 purchases and 2 sales selling 76,665 shares for an estimated $699,858.
- KAPIL DHINGRA sold 21,500 shares for an estimated $408,500
- EMILY LUISA HILL (Chief Financial Officer) has made 0 purchases and 3 sales selling 28,516 shares for an estimated $320,341.
- KONSTANTINOS XYNOS (Chief Medical Officer) has made 0 purchases and 2 sales selling 25,470 shares for an estimated $219,704.
- CHRISTOPHER SARCHI (Chief Commercial Officer) has made 0 purchases and 2 sales selling 20,626 shares for an estimated $154,700.
- ANDREW SCHWENDENMAN (Chief Accounting Officer) has made 0 purchases and 2 sales selling 15,526 shares for an estimated $139,088.
- JOSEPH P SLATTERY sold 5,200 shares for an estimated $113,360
- PHILIP ASTLEY-SPARKE sold 17,657 shares for an estimated $89,697
To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.
This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Investivoq API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.